Altered serum levels of TNF-α, IL-6, and IL-18 in depressive disorder patients

Human Psychopharmacology

Volumn 32, Issue 4, 2017, Pages

  Fan, Ni ^a   Luo, Yayan ^a   Ou, Yufen ^a   He, Hongbo ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

cytokines; depressive disorder; IL 6; lL 18; TNF

Indexed keywords

CITALOPRAM; FLUOXETINE; INTERLEUKIN 18; INTERLEUKIN 6; PAROXETINE; SERTRALINE; TUMOR NECROSIS FACTOR; VENLAFAXINE; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; INTERLEUKIN 18 PROTEIN, HUMAN;

ADULT; ARTICLE; CHINESE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; BLOOD; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL;

ADULT; BIOMARKERS; DEPRESSIVE DISORDER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; LINEAR MODELS; MALE; PSYCHIATRIC STATUS RATING SCALES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85020171551     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2588     Document Type: Article

References (61)

1. Abbasi, S. H., Hosseini, F., Modabbernia, A., Ashrafi, M., & Akhondzadeh, S. (2012). Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebocontrolled study. Journal of Affective Disorders, 141, 308–314.
2. Alboni, S., Cervia, D., Sugama, S., & Conti, B. (2010). Interleukin 18 in the CNS. Journal of Neuroinflammation, 7, 9.
3. Alcocer-Gómez, E., de Miguel, M., Casas-Barquero, N., Núñez-Vasco, J., Sánchez-Alcazar, J. A., Fernández-Rodríguez, A., & Cordero, M. D. (2014). NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain, Behavior, and Immunity, 36, 111–117.
4. Al-hakeim, H. K., Al-Rammahi, D. A., & Al-Dujaili, A. H. (2015). IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. Journal of Affective Disorders, 182, 106–114.
5. Andlin-Sobocki, P., Jönsson, B., Wittchen, H. U., & Olesen, J. (2005). Cost of disorders of the brain in Europe. J Eur J Neurol, 12, 1–27.
6. Bagalman, E., & Napili, A. (2014). Prevalence of mental illness in the United States: Data sources and estimates (English edition), (R43047). Congressional Research Service, USA.
7. Banks, W. A., Kastin, A. J., & Broadwell, R. D. (1995). Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation, 2, 241–248.
8. Berk, M., Wadee, A. A., Kuschke, R. H., & O'Neill-Kerr, A. (1997). Acute phase proteins in major depression. Journal of Psychosomatic Research, 43, 529–534.
9. Bollini, P., Pampalllona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999). Effectiveness of antidepressants: Meta-analysis of dose-effect relationships in randomized clinical trials. The British Journal of Psychiatry, 174, 297–303.
10. Brietzke, E., Stertz, L., Fernandes, B. S., Kauer-Sant'anna, M., Mascarenhas, M., Escosteguy Vargas, A., … Kapczinski, F. (2009). Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. Journal of Affective Disorders, 116, 214–217.
11. Collins, P. Y., Patel, V., Joestl, S. S., March, D., Insel, T. R., & Daar, A. S. (2011). Grand challenges in global mental health. Nature, 475, 27–30.
12. Curtin, F., & Schulz, P. (1998). Multiple correlations and Bonferroni's correction. Biological Psychiatry, 144, 775–777.
13. Dahl, J., Ormstad, H., Aass, H. C., Malt, U. F., Bendz, L. T., Sandvik, L., … Andreassen, O. A. (2014). The plasma levels of various cytokines are increased during ongoing depression and reduced to normal levels after recovery. Psychoneuroendocrinology, 45, 77–86.
14. Dantzer, R., & Kelley, K. W. (2007). Twenty years of research on cytokine induced sickness behavior. Brain, Behavior, and Immunity, 21, 153–160.
15. Dantzer, R., Konsman, J. P., Bluthe, R. M., & Kelley, K. W. (2000). Neural and humoral pathways of communication from the immune system to the brain: Parallel or convergent? Autonomic Neuroscience, 85, 60–65.
16. Dheen, S. T., Kaur, C., & Ling, E. A. (2007). Microglial activation and its implications in the brain diseases. Current Medicinal Chemistry, 14, 1189–1197.
17. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010). A meta-analysis of cytokines in major depression. Biological Psychiatry, 67, 446–457.
18. Duman, R. S. (2004). Depression: A case of neuronal life and death? Biological Psychiatry, 56, 140–145.
19. Einvik, G., Vistnes, M., Hrubos-Strøm, H., Randby, A., Namtvedt, S. K., Nordhus, I. H., … Omland, T. (2012). Circulating cytokine concentrations are not associated with major depressive disorder in a community-based cohort. General Hospital Psychiatry, 34, 262–267.
20. Felderhoff-Mueser, U., Schmidt, O. I., Oberholzer, A., Buhrer, C., & Stahel, P. F. (2005). IL- 18: A key player in neuroinflammation and neurodegeneration? Trends in Neurosciences, 28, 487–493.
21. Fitzgerald, P. J. (2013). Gray colored glasses: Is major depression partially a sensory perceptual disorder? Journal of Affective Disorders, 151, 418–422.
22. Grassi-Oliveira, R., Bauer, M. E., Pezzi, J. C., Teixeira, A. L., & Brietzke, E. (2011). Interleukin-6 and verbal memory in recurrent major depressive disorder. Activitas Nervosa Superior Rediviva, 53, 134–138.
23. Haastrup, E., Bukh, J. D., Bock, C., Vinberg, M., Thorner, L. W., Hansen, T., … Ullum, H. (2012). Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. Journal of Affective Disorders, 136, 134–138.
24. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56–62.
25. Hannestad, J., DellaGioia, N., & Bloch, M. (2011). The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-analysis. Neuropsychopharmacology, 36, 2452–2459.
26. Hestad, K. A., Tonseth, S., Stoen, C. D., Ueland, T., & Aukrust, P. (2003). Raised plasma levels of tumor necrosis factor alpha in patients with depression: Normalization during electroconvulsive therapy. The Journal of ECT, 19, 183–188.
27. Karlović, D., Serretti, A., Vrkić, N., Martinac, M., & Marčinko, D. (2012). Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Research, 198, 74–80.
28. Kubistova, A., Horacek, J., & Novak, T. (2012). Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatria Danubina, 24, 153–156.
29. Lang, U. E., & Borgwardt, S. (2013). Molecular mechanisms of depression: Perspectives on new treatment strategies. Cellular Physiology and Biochemistry, 31, 761–777.
30. Liu, Y., Ho, R. C., & Mak, A. (2012). Interleukin (IL)-6, tumor necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL- 2R) are elevated in patients with major depressive disorder: A metaanalysis and meta-regression. Journal of Affective Disorders, 139, 230–239.
31. Loane, D. J., & Byrnes, K. R. (2010). Role of microglia in neurotrauma. Neurotherapeutics, 7, 366–377.
32. Luo, Y., He, H., Zhang, M., Huang, X., Zhang, J., Zhou, Y., … Fan, N. (2014). Serum levels of TNF-α, IL-6 and IL-18 elevated in chronic schizophrenic patients. Schizophrenia Research, 159, 556–557.
33. Maes, M. (1995). Evidence for an immune response in major depression: A review and hypothesis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 19, 11–38.
34. Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., … Maj, M. (2009). Hypothesis of depression: Leads for future research and new drug developments in depression. Metabolic Brain Disease, 24, 27–53.
35. Marques-Deak, A. H., Neto, F. L., Dominguez, W. V., Solis, A. C., Kurcgant, D., Sato, F., … Prado, E. B. A. (2007). Cytokine profiles in women with different subtypes of major depressive disorder. Journal of Psychiatric Research, 41, 152–159.
36. McAfoose, J., & Baune, B. T. (2009). Evidence for a cytokine model of cognitive function. Neuroscience and Biobehavioral Reviews, 33, 355–366.
37. Merendino, R. A., Di Rosa, A. E., Di Pasquale, G., Minciullo, P. L., Mangraviti, C., Costantino, A., … Gangemi, S. (2002). Interleukin-18 and CD30 serum levels in patients with moderate-severe depression. Mediators of Inflammation, 11, 265–267.
38. Miller, A. H., Maletic, V., & Raison, C. L. (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65, 732–741.
39. Mota, R., Gazal, M., Acosta, B. A., de Leon, P. B., Jansen, K., Pinheiro, R. T., … Kaster, M. P. (2013). Interleukin-1β is associated with depressive episode in major depression but not in bipolar disorder. Journal of Psychiatric Research, 47, 2011–2014.
40. Muller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Muller, B., … Riedel, M. (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry, 11, 680–684.
41. Munkholm, K., Weikpo, P., Kessing, L. V., & Vinberg, M. (2015). Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain, Behavior, and Immunity, 43, 205–213.
42. Munzer, A., Sack, U., Mergl, R., Schönherr, J., Petersein, C., Bartsch, S., … Himmerich, H. (2013). Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins (Basel), 5, 2227–2240.
43. Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., … Miller, A. H. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alfa. The New England Journal of Medicine, 344, 961–966.
44. Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta-Soares, G. B., Frey, B. N., … Soares, J. C. (2008). Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Human Psychopharmacology, 23, 87–94.
45. Perry, V. H., Cunningham, C., & Holmes, C. (2007). Systemic infections and inflammation affect chronic neurodegeneration. Nature Reviews. Immunology, 7, 161–167.
46. Prossin, A. R., Koch, A. E., Campbell, P. L., McInnis, M. G., Zalcman, S. S., & Zubieta, J. K. (2011). Association of plasma interleukin-18 levels with emotion regulation and muopioid neurotransmitter function in major depression and healthy volunteers. Biological Psychiatry, 69, 808–812.
47. Raedler, T. J. (2011). Inflammatory mechanisms in major depressive disorder. Current Opinion in Psychiatry, 24, 519–525.
48. Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., … Miller, A. H. (2005). Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. The Journal of Clinical Psychiatry, 66, 41–48.
49. Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., … Miller, A. H. (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: Relationship to CNS immune responses and depression. Molecular Psychiatry, 15, 393–403.
50. Rief, W., Mills, P. J., Ancoli-Israel, S., Ziegler, M. G., Pung, M. A., & Dimsdale, J. E. (2010). Overnight changes of immune parameters and catecholamines are associated with mood and stress. Psychosomatic Medicine, 72, 755–762.
51. Sartorius, N. (2001). The economic and social burden of depression. The Journal of Clinical Psychiatry, 62, 8–11.
52. Schiepers, O. J., Wichers, M. C., & Maes, M. (2005). Cytokines and major depression. Prog. Neuropsychopharmacol. Biological Psychiatry, 29, 637–638.
53. Thomas, A. J., Davis, S., Morris, C., Jackson, E., Harrison, R., & O'Brien, J. T. (2005). Increase in interleukin-1beta in late-life depression. The American Journal of Psychiatry, 162, 175–177.
54. Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003). Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology, 170, 429–433.
55. Vogelzangs, N., Beekman, A. T., van Reedt Dortland, A. K., Schoevers, R. A., Giltay, E. J., de Jonge, P., & Penninx, B. W. (2014). Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology, 39, 1624–1634.
56. Xiu, M. H., Chen, D. C., Wang, D., Zhang, K., Dong, A., Tang, W., … Zhang, X. Y. (2012). Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology. Journal of Psychiatric Research, 46, 1093–1098.
57. Yang, L., Zhang, Z., Sun, D., Xu, Z., Zhang, X., & Li, L. (2010). The serum interleukin-18 is a potential marker for development of post-stroke depression. Neurological Research, 32, 340–346.
58. Yoshimura, R., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., Katsuki, A., Atake, K., … Nakamura, J. (2013). Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. Hum. Psychopharmacol Clin Exp, 28, 466–470.
59. Yoshimura, R., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., Ueda, N., & Nakamura, J. (2009). Higher plasma interleukin-6 (IL-6) level is associated with SSRI or SNRI-refractory depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 33, 722–726.
60. Zeugmann, S., Quante, A., Heuser, I., Schwarzer, R., & Anghelescu, I. (2010). Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. The Journal of Clinical Psychiatry, 71, 1007–1016.
61. Zunszain, P. A., Hepgul, N., & Pariante, C. M. (2013). Inflammation and depression. Current Topics in Behavioral Neurosciences, 14, 135–151.